Factor X

DGAP-News: Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell replacement therapy to advance a 'functional cure' for diabetes

Retrieved on: 
Tuesday, May 17, 2022
Diabetes, Disease, IPSC, Transplant, DGAP, Pancreas, International Diabetes Federation, Cell, Type 2 diabetes, University, Degenerative disease, Immune system, Twitter, Regenerative medicine, Gene, Blood, Cell potency, Quality of life, Nobel Prize, Insulin, Hormone, Factor X, Potency (pharmacology), Survival, Haemophilia, Science, Nerve Damage, Chicago (franchise), Adult, T2D, Biotechnology, IPS, Human, Heart, Therapy, LinkedIn, Protein, Environment, Patient, Neurology, Kidney, Neuron, Industry, Technology, Safety, Workload, News, Eye, ESG, Vaccine, Fine chemical, Pharmaceutical industry, T1D, Evotec

Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry.

Key Points: 
  • Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry.
  • The Cell Pouch, as part of the Cell Pouch System, is a proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells.
  • In the type 1 form of diabetes (T1D), beta cells are destroyed by the patients own immune system.
  • Furthermore, beta cell replacement therapy also has the potential to prevent or reverse the decline in beta cell function in type 2 diabetes.

Inventiva reports 2022 First Quarter Financial Information and provides clinical development update

Retrieved on: 
Monday, May 16, 2022
Part, European Investment Bank, Company, IVA, Pharmacology, NASH, ISIN, Nasdaq, Degenerative disease, Patient, Biology, AbbVie, SGLT2, Phase, Pharmacokinetics, USD, Computational chemistry, COVID-19, Adult, Mucopolysaccharidosis, Fatty liver disease, Research, MPS, Psoriasis, Conference, T2D, Type 2 diabetes, Chronic liver disease, Empagliflozin, Group, Factor X, VI, Online gambling, Pharmaceutical industry, Cryptocurrency, Video game, EU, Euronext Paris, NAFLD

R&D expenses for the first quarter, mainly driven by the development of lanifibranor in NASH, were up 74% compared to the first quarter of 2022.

Key Points: 
  • R&D expenses for the first quarter, mainly driven by the development of lanifibranor in NASH, were up 74% compared to the first quarter of 2022.
  • This significant increase in R&D expenses is driven by the costs associated with the NATiV3 Phase III clinical trial with lanifibranor in NASH.
  • Net cash used in investing activities for the first quarter of 2022 amounted to 0.1 million, compared to 1.1 million in the first quarter of 2021.
  • No net cash from financing activities was generated over the first quarter of 2022, same as for the first quarter of 2021.

Flamingo Therapeutics to Present at the BioEquity Europe and Knowledge for Growth Conferences in May 2022

Retrieved on: 
Monday, May 16, 2022
Knowledge, Genome, PMV, Therapy, Listeria monocytogenes non-coding RNA, Biotechnology, RNA, LinkedIn, Ionis Pharmaceuticals, Factor X, CA, Nightclub, Flamingo

LEUVEN, Belgium, May 16, 2022 /PRNewswire/ -- Flamingo Therapeutics, a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that Mike Garrett, Chief Executive Officer, will present a company overview at the BioEquity Europe and Knowledge for Growth meetings, taking place May 16-18 in Milan, Italy and May 18-19 in Ghent, Belgium.

Key Points: 
  • LEUVEN, Belgium, May 16, 2022 /PRNewswire/ -- Flamingo Therapeutics, a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that Mike Garrett, Chief Executive Officer, will present a company overview at the BioEquity Europe and Knowledge for Growth meetings, taking place May 16-18 in Milan, Italy and May 18-19 in Ghent, Belgium.
  • The Flamingo management team will also participate in one-on-one meetings with investors during both conferences.
  • The presentations for both conferences will be available on-demand for registered attendees.
  • Flamingo has a discovery alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors Kurma Partners and PMV.

Inventiva secures a €50 million credit facility from the European Investment Bank

Retrieved on: 
Monday, May 16, 2022
Single-tranche CDO, European Investment Bank, COVID-19, Company, IVA, Pharmacology, NASH, ISIN, Nasdaq, Exercise, Degenerative disease, Patient, Investment, AbbVie, Biology, Vaccine, Phase, Pharmacokinetics, Computational chemistry, Adult, Mucopolysaccharidosis, Fatty liver disease, Research, MPS, Climate, Partnership, Chronic liver disease, Union, EIB, Factor X, VI, Achievement, Pharmaceutical industry, Security (finance), EU, Euronext Paris

The facility is divided into two tranches of 25 million each.

Key Points: 
  • The facility is divided into two tranches of 25 million each.
  • The disbursement of the first tranche (Tranche A) is subject to the completion of certain conditions precedent specified in the credit facility agreement.
  • The maturity date of any borrowings under the facility is four years after disbursement of Tranche A and three years after disbursement of Tranche B.
  • Jean Volatier, Chief Financial Officer of Inventiva, stated: We are very pleased with this credit facility, one of the largest granted by the EIB to a biotech.

VolitionRx Limited Announces First Quarter 2022 Financial Results and Business Update

Retrieved on: 
Wednesday, May 11, 2022
Cancer, Quality, Company, Disease, Capital market, Chromatin, Nu, New, 2021 Essex County Council election, Patient, Science, Quality of life, Lung cancer, Point-of-care testing, Proteomics, COVID-19, Point, Research, Mass spectrometry, Epigenetics, Marketing, Life, GenomeWeb, Conference call, NYSE, Software development process, Technology, Sale, Colorectal cancer, NETS, Lung, Animal, Sepsis, Diagnosis, Factor X, Achievement, Video game, Pharmaceutical industry, Sales, Veterinary medicine, Video game console, Medical device, Online shopping, Neutrophil extracellular traps, Conference, Volition, Nucleosome

AUSTIN, Texas, May 11, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2022. Volition management will host a conference call tomorrow, May 12 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.

Key Points: 
  • Conference call to discuss financial and operational results scheduled for Thursday, May 12, at 8:30 a.m. U.S. Eastern Time
    AUSTIN, Texas, May 11, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2022.
  • Volition management will host a conference call tomorrow, May 12 at 8:30 a.m. U.S. Eastern Time to discuss these results.
  • Cash and cash equivalents as of March 31, 2022, totaled approximately $23.7 million compared with $20.6 million as of December 31, 2021.
  • The call will provide an update on important events which have taken place in the first quarter of 2022 and upcoming milestones.

Flare Therapeutics to Present at the Bank of America Securities 2022 Healthcare Conference

Retrieved on: 
Thursday, May 5, 2022
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Factor X, Daphne, Biotechnology, Flare, Drug discovery, Inflammation, Cancer, Neurology, LinkedIn, Disease, Bank, Conference, Lists of diseases, Third Rock Ventures, Biology, Therapy, Pharmaceutical industry

Flare Therapeutics, a [privately-held] biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced that Daphne Karydas, chief operating officer and chief financial officer will present at the upcoming Bank of America Securities 2022 Healthcare Conference on Thursday, May 12th at 10:00 a.m. PT in Las Vegas, Nevada.

Key Points: 
  • Flare Therapeutics, a [privately-held] biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced that Daphne Karydas, chief operating officer and chief financial officer will present at the upcoming Bank of America Securities 2022 Healthcare Conference on Thursday, May 12th at 10:00 a.m. PT in Las Vegas, Nevada.
  • Flare Therapeutics is a biotechnology company opening a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines.
  • Based on insights from the seminal work of its scientific founders, Flares team has uncovered switch sites, druggable regions that are key targets for transcription factor regulation to address mutations that cause disease.
  • Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors and Eventide Asset Management.

Rooted in Healthy Soil: Conservation Practices Deliver Economic Rewards

Retrieved on: 
Tuesday, May 3, 2022
Agricultural Research Service, Agriculture, Water, Seed, Soil, Safety, U.S. Department of Defense Strategy for Operating in Cyberspace, U.S. Department of Agriculture Cotton Annex, Biodiversity, Farmer, Health, Efficiency, Method, Erosion, Weed control, USDA, Solution, Factor X, Syngenta

GREENSBORO, N.C., May 3, 2022 /PRNewswire/ -- Thirty years ago, an Iowa farmer was forced by circumstance to seek an alternative way to till his fields. That decision made out of necessity delivered unexpected economic, soil health and yield rewards for Wayne Fredricks. As a result, Fredericks is a passionate proponent of no-till agriculture.

Key Points: 
  • That decision made out of necessity delivered unexpected economic, soil health and yield rewards for Wayne Fredricks.
  • Conservation practices for farmers can deliver economic rewards, in addition to improving soil health.
  • "Our soybeans grew well that summer; the weed control was good; and the yields were good," he said.
  • Starting from the ground up, experts and growers alike are seeing the benefits healthy soil has on conservation, yield potential and earning potential.

AMERICAN SKIN ASSOCIATION ANNOUNCES 2022 RESEARCH GRANTS FOR SKIN CANCER AND DISEASES

Retrieved on: 
Monday, May 2, 2022
Dermatology, Treatment, Gene expression, Name, Stiefel, Population, University, Topical medication, Transcription factor, Role, Physician, Howard University College of Medicine, Research, ASA, Mount Sinai, GAPDHS, Patient, Doctor of Philosophy, Atopic dermatitis, Icahn School of Medicine at Mount Sinai, Association, Immunotherapy, Diagnosis, MAC, Leadership, Prognosis, Melanoma Research, View, Skin cancer, Sirolimus, Seal, Psoriasis, C1-inhibitor, Factor X, Foundation, Multimedia, Pharmaceutical industry, Vaccine, Melanoma, Color, Vitiligo, Medicine, MD, Mycosis, Skin

NEW YORK, May 2, 2022 /PRNewswire/ -- American Skin Association has announced the names of the two awardees receiving the coveted research grant under the ASA Milstein Research Scholar Awards program.

Key Points: 
  • NEW YORK, May 2, 2022 /PRNewswire/ -- American Skin Association has announced the names of the two awardees receiving the coveted research grant under the ASA Milstein Research Scholar Awards program.
  • Over the years, the Stiefel Familylongtime supporters of ASAhas generously contributed $600,000 to support grants for melanoma research.
  • "These grants in support of cutting-edge dermatological research are crucial in furthering ASA's goal of defeating skin cancers like melanoma.
  • ASA provides significant research awards to established investigators and medical students studying melanoma, non-melanoma skin cancer, and other skin diseases.

Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
Monday, May 2, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Genetics, Forward-looking statement, Outline, Nasdaq, Factor X, CNS, Institutional review board, Cell, AAV, Patient, Gene, Annual report, Genetic code, U.S. Securities and Exchange Commission, 2021 Essex County Council election, Society, Traffic barrier, Technology, Research, Central nervous system, Therapy, Pharmaceutical industry, Vaccine, Powder metallurgy, Wood drying, Sangamo Therapeutics

Presentations will focus on the progression of Sangamos pre-clinical programs emerging from its genomic engineering platform.

Key Points: 
  • Presentations will focus on the progression of Sangamos pre-clinical programs emerging from its genomic engineering platform.
  • With protection from the blood-brain barrier, current gene delivery to the CNS continues to be an obstacle.
  • Sangamos AAV capsids are designed to overcome that barrier, providing broad CNS access while minimizing exposure to a patients pre-existing anti-AAV antibodies.
  • Sangamo will also present data from its CAR-Treg cell therapy platform, including outlining advancements in pre-clinical allogeneic Treg engineering.

Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Retrieved on: 
Thursday, April 28, 2022
PD-1, Squamous cell carcinoma, ASCO, Program, IL-9, LinkedIn, Cancer, Patient, Twitter, IL-2, GLOBE, Aryl hydrocarbon receptor, Annual general meeting, Factor X, NF2, Private Securities Litigation Reform Act, American Society of Clinical Oncology, RAS, Clinical trial, BMS, AHR, Abstract (summary), Immunology, Standard of care, Nivolumab, EHE, Tumor microenvironment, Cytokine, Kynurenine, Bristol Myers Squibb, Society, Hippopotamus, TAZ, SEC, TEAD, Pharmaceutical industry

BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that it will be presenting two trial-in-progress posters at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

Key Points: 
  • BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that it will be presenting two trial-in-progress posters at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.
  • The presentations will include overviews of the clinical trials for Ikenas novel TEAD inhibitor, IK-930, and aryl hydrocarbon receptor (AHR) antagonist, IK-175.
  • BMS has the right to exclusively license the program through the completion of the Phase 1b portion of the clinical trial.
  • Ikena OncologyTM is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer.